Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50

Clinical Therapeutics

Volumn 21, Issue 3, 1999, Pages 523-534

  Roach, Paris ^a   Trautmann, Michael ^a   Arora, Vipin ^a   Sun, Bin ^a   Anderson Jr , James H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Hemoglobin A(1c); Human insulin; Insulin lispro; Insulin mixtures; Nocturnal hypoglycemia

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN LISPRO; ISOPHANE INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN RESPONSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

EID: 0032951336     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88307-1     Document Type: Article

References (24)

1. 1. Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes. Diabetes Rev. 1995;3: 308-334.
2. 2. IMS Health, 1997. Data on file. Indianapolis, Ind: Eli Lilly and Company.
3. 3. Bell DSH, Clements RS, Perentesis G, et al. Dosage accuracy of self-mixed vs premixed insulin. Arch Intern Med. 1991; 151:2265-2269.
4. 4. Coscelli C, Calabrese G, Fedele D, et al. Use of premixed insulin among the elderly: Reduction of errors in patient preparation of mixtures. Diabetes Care. 1992; 5:1628-1630.
5. 5. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28) Pro(B29)]-human insulin: A rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396-402.
6. 6. Anderson JH Jr, Brunelle RL, Koivisto VA, and the Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 1997;46:265-270,
7. 7. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:1249-1255.
8. 8. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care. 1983;6: 374-377.
9. 9. Radziuk JR, Bradley B, Welsh L, et al. Neutral protamine lispro: Activity profile of s.c. administration with and without admixture of soluble lispro. Diabetologia. 1996;39(Suppl 1):A224. Abstract.
10. 10. Janssen MMJ, Casteleijn S, Deville W, et al. Nighttime insulin kinetics and glycemic control in type I diabetes patients following administration of an intermediate-acting lispro preparation. Diabetes Care. 1997;20:1870-1873.
11. 11. Accuchek® Advantage™ |package insert|. Indianapolis, Ind: Boehringer Mannheim Corporation; 1994.
12. 12. Accuchek® Easy™ |package insert|. Indianapolis, Ind: Boehringer Mannheim Corporation; 1994.
13. 13. Koch GG. The use of non-parametric methods in statistical analysis of the two-period change-over design. Biometrics. 1972;28:577-584.
14. 14. Taulbee JD. A note on the use of non-parametric methods in the statistical analysis of the two-period changeover design. Biometrics. 1982;38:1053-1055.
15. 15. Girizzle JE. The two-period change-over design and its use in clinical trials. Biometrics. 1965;21:467-480.
16. 16. Heise T, Weyer C, Serwas A, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care. 1998;21:800-803.
17. 17. Vignati L, Anderson JH Jr., Iversen PH. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin dependent diabetes mellitus. Clin Ther. 1997;19:1408-1421.
18. 18. Anderson JH Jr., Brunelle RL, Koivisto VA, et al. Multicenter Insulin Lispro Study Group: Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther. 1997;19:62-72.
19. lc) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968-983.
20. 20. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
21. 21. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endcr Rev. 1998;19:583-592.
22. 22. Ceriello A. The emerging role of postprandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabetic Med. 1998;15:188-193.
23. 23. Zinman B, Tildesley H, Chiasson JL, et al. Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes. 1997; 46:440-443.
24. 24. Ceriello A, Taboga C, Tonutti L, et al. Post-meal coagulation activation in diabetes mellitus: The effect of acarbose. Diabetologia. 1996;39:469-473.